# Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

> **NCT03136484** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 788 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Canagliflozin
- **DRUG:** Placebo (canagliflozin)
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT03136484
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-15
- **Primary completion:** 2018-10-16
- **Final completion:** 2018-11-16
- **Target enrollment:** 788 (ACTUAL)
- **Last updated:** 2020-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03136484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03136484, "Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03136484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*